Canada makes history as the first G7 nation to approve generic, Health Canada says
After months of anticipation and speculation, Health Canada has authorized the first generic version of semaglutide injection in the G7, a regulatory milestone that could deliver significant cost relief to Canadian employer benefit plans and the broader healthcare system.
The approval, announced April 28, covers a generic semaglutide injection manufactured by Dr. Reddy's Laboratories. The product is a generic equivalent of the brand name drug Ozempic and is indicated for the once-weekly treatment of type 2 diabetes in adults to manage blood sugar levels, according to its press release Tuesday.
Health Canada confirmed the drug met all regulatory criteria for safety, efficacy, and quality following a thorough review.
"Health Canada completed the review of Dr. Reddy's submission within its target timeline of 180 days. The time the manufacturer takes to provide the required or missing data does not count toward the 180-day target, and once this information is received, a second round of review begins, extending the total time for the review," the federal department said in its official statement.
The decision notably carries immediate relevance for plan sponsors and benefits administrators. Semaglutide has become one of the most prescribed - and most expensive - diabetes medications in Canada, placing growing pressure on drug plan budgets.
Additionally, with generic medications in Canada typically priced 45 to 90 per cent below their brand name equivalents, the introduction of lower-cost alternatives could meaningfully reduce per-claimant costs for plans covering diabetes therapies.
Health Canada disclosed that it is currently reviewing eight additional submissions for generic semaglutide from different manufacturers, with regulatory decisions expected in the coming weeks and months. Greater market competition among generic producers would likely drive prices down further, compounding savings for payers.
For benefits consultants and plan sponsors grappling with rising drug trend rates, the approval represents a welcome shift in the cost equation. However, formulary decisions, substitution policies, and provincial reimbursement frameworks will ultimately determine how quickly generic semaglutide reaches plan members.
Health Canada has committed to ongoing safety and effectiveness monitoring of all approved generic semaglutide products, providing an added layer of assurance for plan sponsors evaluating formulary changes.
